Skip to content
type1.science

FreeStyle Libre 3 Plus

Abbott

What it is

A small, factory-calibrated, 15-day glucose sensor for ages 2+ under its US label, with several specifically supported AID pairings. Accuracy evidence includes a study using the same sensing element in Libre 2 Plus. Certain sensor lots are subject to a Class I recall; access and apps differ by country.

Editorial review: .

Most recent recorded citation date: 2026-09-15. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Country-specific accessRegulator-approvedcgm

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
Benefit or performance
Accuracy: US-label MARD is 8.2% in both adult and age 6–17 analyses. The journal reports a different analysis of the shared sensing element. This retained editorial rating also reflects unresolved quality concerns; it is not a measured accuracy or recall-risk score.[1]
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
US, UK, German and Canadian product pathways are documented. Australia currently has a mylife Loop pathway; expanded eligible NDSS access starts 1 October 2026.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the full discussion and original sources for follow-up duration and study limitations.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Score limitations. These retained scores are editorial judgments, not validated conversions of MARD, recall reports or user experience. The accuracy evidence is bridged from Libre 2 Plus; journal and US-label analyses differ. The previous recall-related score reduction has no calibrated numerical risk model.

Default calculation: 70 × 20 + 65 × 15 + 87 × 15 + 85 × 10 + 95 × 10 + 80 × 10 + 92 × 10 + 0 × 5 + 74 × 5 = 7570; divide by total weight 100. Unrounded weighted result: 75.7.

Accuracy70

US-label MARD is 8.2% in both adult and age 6–17 analyses. The journal reports a different analysis of the shared sensing element. This retained editorial rating also reflects unresolved quality concerns; it is not a measured accuracy or recall-risk score.[1]

Low lag65

The shared-sensing-element study estimated mean lag of 1.7 minutes in adults and 0.9 minutes in children. These are method-dependent study estimates, not a fixed delay during every glucose change; this score is editorial.[3]

Interoperability87

The German manufacturer page names Libre 3 Plus pairings with mylife Loop and Tandem Control-IQ+. US pairings and community software are separately documented below; compatibility depends on country and system version.[10]

Sensor lifespan85

Up to 15 days is the labeled maximum wear period, not a guarantee that every sensor lasts 15 days.[1]

No calibration95

Factory-calibrated, but meter checks remain necessary in the circumstances specified by the label, including the first-12-hour inaccurate-sensor symbol.[1]

Alerts & prediction80

The current US Libre app provides glucose alarms, including urgent low below 55 mg/dL (3.1 mmol/L); phone settings and Silent Mode affect notification delivery.[1]

Form factor92

The US specification is 21 mm diameter, 2.9 mm high and 1 gram, with a 60-minute warm-up. The comfort rating is editorial, not a comparative trial result.[1]

Ketone sensing0

This sensor measures glucose, not ketones.[1]

Access & cost74

NDSS announced expanded Australian access for eligible registrants from 1 October 2026. Eligibility and a professional update of CGM access remain required; this does not establish universal or free access.[15]

The full picture

The FreeStyle Libre 3 Plus is distinct from the original 14-day Libre 3. Its US label permits up to 15 days of wear from age 2, including use with specifically compatible automated insulin delivery (AID) systems. The sensor is worn on the back of the upper arm. Each connected pump has its own age, software and treatment indications.21

Accuracy: identify the sensor and the analysis

The Abbott-funded 15-day study used Libre 2 Plus sensors, not the smaller Libre 3 Plus housing. The authors explain that Libre 3 Plus uses the same sensing element. The journal's laboratory-reference analysis included 149 adults with 20,619 paired readings and 124 children aged 6–17 with 7,075 pairs: MARD was 8.2% and 8.1%, respectively. MARD describes average relative disagreement with a reference, not an individual's expected error. A separate group of 12 children aged 2–5, compared with a capillary meter rather than laboratory YSI, contributed 477 pairs with 11.2% MARD.3

The current US label reports a different analysis: 20,497 adult pairs and 7,025 age-6–17 pairs, both with 8.2% MARD. Its youngest-child table uses 135 clinic pairs from 10 of the 12 children and reports 9.7% MARD. These counts must not be combined with the journal's values; this review has not reconciled all differences in included pairs. The studies included insulin-treated diabetes, not exclusively adults with type 1 diabetes.13

Performance varies with glucose range and wear day. In the journal, when laboratory glucose was below 70 mg/dL (3.9 mmol/L), 97.1% of 3,259 adult pairs and 98.0% of 693 older-child pairs were within 15 mg/dL (0.8 mmol/L) of the reference. That agreement statistic is not a low-glucose MARD or evidence of superiority to another sensor. The paper's estimated mean lag was 1.7 minutes in adults and 0.9 minutes in children, with substantial variability; it does not establish a universal delay. Its 15-day labeling does not establish that every sensor survives the full wear period.3

Safety notices and meter backup

The FDA's 4 February 2026 communication update identifies certain original Libre 3 and Libre 3 Plus sensors with incorrect low readings as a Class I recall. Its early alert was dated 2 December 2025. The FDA says Abbott reported 860 serious injuries and 7 deaths associated with the issue through 7 January 2026; these reports do not establish a causal rate among all users. Check the exact sensor serial number using the notice's official checker. If affected, the notice instructs users to stop using and dispose of the sensor and request a free replacement. This is a specified-product recall, not a finding that every Libre sensor is affected.4

A separate 23 January 2026 FDA warning letter identified deficiencies in design transfer and finished-device accuracy acceptance testing. It questioned whether upstream component testing adequately established accuracy after final assembly, sterilisation and programming. The letter does not establish the current defect rate or prove that subsequent remediation is complete.5

Factory calibration does not eliminate all fingersticks. Current US instructions require a meter for treatment decisions when the first-12-hour inaccurate-sensor symbol appears, readings or alarms conflict with symptoms or expectations, or a current glucose number is unavailable. More than 1,000 mg/day of vitamin C may falsely raise Plus readings. Follow the applicable local sensor and pump instructions.1

Daily use

The US sensor specification is 21 mm across, 2.9 mm high and 1 gram, with a 60-minute warm-up. Its IP27 water rating permits immersion to 1 metre for 30 minutes; this does not establish the phone or reader's water resistance. App and reader cannot be interchanged midway through a sensor session. Current US Libre app alarms include urgent low below 55 mg/dL (3.1 mmol/L); Silent Mode can mute notifications. The app's “Glucose Going Low” message concerns a projected low within 15 minutes and should not be confused with every region's alarm feature set.1

Compatibility and access are regional

Documented US pairings include Omnipod 5 (rollout announced 3 June 2026), iLet, t:slim X2 with Control-IQ+, and twiist. These are specific supported combinations, not compatibility with every pump, phone or version.6879

Abbott Germany documents mylife Loop and Tandem Control-IQ+ pairings with Plus. Its UK and Canadian pages document local Plus product pathways; reimbursement still depends on eligibility. In Australia, Abbott documents the mylife Loop pathway and standalone expansion from 1 October 2026. NDSS announced on 14 August 2026 that all eligible registrants can access Plus from that October date after consulting an authorised professional and updating CGM access. That expansion is future access as of this review, not already active on 17 September.1012131415

Separately, Trio v1.0 introduced direct Libre 3 / Libre 3 Plus support in beta on 15 September 2026. Its release describes a five-minute reading cadence and no LibreView/LibreLink/LibreLinkUp upload through that integration. This community-software release does not establish a regulated AID pairing.11

What's next for this

  • →Expanded Australian NDSS access for eligible registrants, including standalone use · 1 October 2026

Sources

  1. [1]
    Libre app US User Manual — ART48742-103 Rev A · Manufacturer — US labeling for original Libre 3 and Libre 3 Plus; indications and performance tables are separate.
  2. [2]
    FDA K233537 — original Libre 3 and Libre 3 Plus indications · Regulatory decision · 2024-04-23 — Plus is indicated from age 2 with compatible AID; the original US sensor is age 4+ and is not for AID.
  3. [3]
    Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design · Peer-reviewed study · 2025-04-04 — Abbott-funded study used Libre 2 Plus sensors; authors describe the shared sensing element in Libre 3 Plus. Journal and current US-label analysis counts differ.
  4. [4]
    FDA recall communication — certain Libre 3 and Libre 3 Plus sensors with incorrect low readings · Regulatory decision · 2026-02-04 — February 4 is the communication update announcing Class I classification, not an independently established classification decision date.
  5. [5]
  6. [6]
  7. [7]
  8. [8]
  9. [9]
  10. [10]
  11. [11]
  12. [12]
  13. [13]
  14. [14]
  15. [15]